Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Lymphoid 1Gastrointestinal 1Dermatologic 1

Conditions

Sarcoma, Kaposi 1Recurrence 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1HIV Infections 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Valganciclovir 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Biopsy 3Bevacizumab 3technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 2Nivolumab 2tocilizumab 1pomalidomide 1pembrolizumab 1liposomal doxorubicin 1emvododstat 1efineptakin alfa 1cabozantinib 1Zidovudine 1Sunitinib 1Polymerase Chain Reaction 1Nelfinavir 1Maraviroc 1Lenalidomide 1Ipilimumab 1Immunohistochemistry 1Imatinib Mesylate 1HhAntag691 1Gene Expression Profiling 1Etoposide 1Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination 1CTLA-4 Antigen 1Antiretroviral Therapy, Highly Active 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma, Kaposi × Antiretroviral Therapy, Highly Active × Clear all
NCT02595866 2024-08-09

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

National Cancer Institute (NCI)

Phase 1 Completed
58 enrolled 17 charts
DermatologicGastrointestinalLymphoidSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Non-Hodgkin, Melanoma, Neoplasm Metastasis, Neoplasms, Recurrence, Sarcoma, Kaposi, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡